SomaLogic, Inc. (SLGC)

Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash   Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business    Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even    Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced the strategic sale of SomaLogic to Illumina, Inc. (NASDAQ: ILMN) (“Illumina”), including SomaScan® Assay Services, Authorized Sites and KREX™ for an upfront payment of $350 million in cash at closing and up to $75 million in cash in near-term milestone payments, for aggregate cash consideration of up to $425 million, plus specified sales royalties on SOMAmer-based next-generation sequencing (NGS) library preparation kits (Illumina Protein Prep).

Stockholder Approval Represents Key Milestone Toward Completion of Standard BioTools Transaction Combination Will Create a Diversified Leader in Life Sciences Tools BOULDER, Colo. , Jan. 4, 2024 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC) ("the Company"), a leader in proteomics technology, today announced that, based on the preliminary vote count provided by its proxy solicitors following the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today, SomaLogic stockholders voted to approve the transaction with Standard BioTools Inc. (Nasdaq: LAB) ("Standard BioTools").

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), is demanding the Company finally answer key questions related to its repeated adjournments of the Special Meeting of Shareholders (the “Special Meeting”) pertaining to the proposed merger (the “Proposed Merger” or the “Transaction”) with Standard BioTools Inc.

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today issued the below statement regarding today's multiple adjournments of the Special Meeting of Shareholders (the “Special Meeting”) related to the proposed merger (the “Proposed Merger” or the “Transaction”) with Standard BioTools Inc. (“Standard BioTools”).

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Both Recommend SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioTools BOULDER, Colo. , Jan. 2, 2024 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC) ("the Company"), a leader in proteomics technology, today sent the following open letter to stockholders urging them to vote "FOR" the value maximizing transaction with Standard BioTools.

BOSTON--(BUSINESS WIRE)--Boston Millennia Partners (“Boston Millennia”), a significant shareholder of SomaLogic (the “Company”) (Nasdaq: SLGC) today announced that it intends to vote against the Company's planned merger (the “Merger”) with Standard BioTools Inc. (Nasdaq: LAB).

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today issued the following statement regarding the proposed merger (the “Proposed Merger” or the “Transaction”) with Standard BioTools Inc. (“Standard BioTools”) (Nasdaq: LAB). We would like to thank the many shareholders and stakeholders who have engaged in a.

Glass Lewis Recommendation Emphasizes Strong Strategic Rationale and Thorough Process  ISS Reiterates Recommendation Following Public Commentary Recommendations Reiterate that Value Maximizing Transaction Is in the Best Interests of Stockholders; Board Urges Stockholders to Vote "FOR" the Transaction   BOULDER, Colo. , Dec. 29, 2023 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC), a leader in proteomics technology, today announced that Glass Lewis & Co. ("Glass Lewis") has recommended that SomaLogic stockholders vote "FOR" the pending merger with Standard BioTools at the company's Special Meeting of Stockholders to be held on January 4, 2024.

Continues to Recommend Stockholders Vote "FOR" Pending Merger ISS has Dismissed Madryn's Misleading Claims and Reaffirms that Stockholders Vote "FOR" the Merger BOULDER, Colo. , Dec. 29, 2023 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC) ("the Company"), a leader in proteomics technology, today sent the following open letter to stockholders reiterating the Board's belief that the proposed transaction between SomaLogic and Standard BioTools is in the best interest of all stockholders.

BOULDER, Colo. , Dec. 28, 2023 /PRNewswire/ -- Dr. Larry Gold, the founder of SomaLogic, Inc. ("SomaLogic" or the "Company") (Nasdaq: SLGC) and Dr. Jason Cleveland, SomaLogic's current Chief Technology Officer, are issuing the below letter to SomaLogic's stockholders regarding their opposition to the Company's proposed merger with Standard BioTools, Inc. ("Standard") (Nasdaq: LAB).

SomaLogic Publishes Key Correspondence from LabCorp CEO Omitted by Madryn in its Attempt to Undermine Confidence in SomaLogic's Thorough Strategic Process Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders BOULDER, Colo. , Dec. 26, 2023 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC), a leader in proteomics technology, today issued the following statement in response to a press release issued by Madryn Asset Management, LP ("Madryn") on December 26, 2023, regarding the pending merger with Standard BioTools (Nasdaq: LAB): On Christmas Eve (December 24, 2023), Madryn resorted to manufacturing rumors of a third party's interest in SomaLogic as its latest attempt to stand in the way of a Board-approved transaction.

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today disclosed that the Transaction Committee of the Company's Board of Directors (the “Transaction Committee”) did not pursue a substantive dialogue with Laboratory Corporation of America Holdings (“Labcorp”) (NYSE: LH) – one of the industry's most logical st.

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today issued the following letter to Institutional Shareholder Services, Inc. (“ISS”) following ISS' publication of a report that recommends “cautionary support” for the Company's proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (“Standard Bi.

CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management (“Tikvah”), a significant shareholder of Somalogic (the “Company”) (Nasdaq: SLGC) with voting rights for 5.9 million shares, or 3.1% of the outstanding shares of Somalogic, today announced that it intends to vote against the Company's proposed merger with Standard BioTools Inc. (Nasdaq: LAB). Tikvah believes the proposed merger is not in the best interest of Somalogic shareholders, echoing reasons elaborated by other investors opposing the mer.

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today reiterated its view that there is a viable alternative to the proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (Nasdaq: LAB). Madryn issued the following statement: It is our view that SomaLogic's consider.

Company Urges Stockholders to Vote “FOR” Value Maximizing Transaction at Upcoming Special Meeting Company Urges Stockholders to Vote “FOR” Value Maximizing Transaction at Upcoming Special Meeting